273 related articles for article (PubMed ID: 27870568)
41. Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors.
Armenian SH; Horak D; Scott JM; Mills G; Siyahian A; Berano Teh J; Douglas PS; Forman SJ; Bhatia S; Jones LW
Biol Blood Marrow Transplant; 2017 Apr; 23(4):700-705. PubMed ID: 28065839
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
[TBL] [Abstract][Full Text] [Related]
43. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Brunner AM; Kim HT; Coughlin E; Alyea EP; Armand P; Ballen KK; Cutler C; Dey BR; Glotzbecker B; Koreth J; McAfee SL; Spitzer TR; Soiffer RJ; Antin JH; Ho VT; Chen YB
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1374-80. PubMed ID: 23791626
[TBL] [Abstract][Full Text] [Related]
44. Decline in the Use of Surgical Biopsy for Diagnosis of Pulmonary Disease in Hematopoietic Cell Transplantation Recipients in an Era of Improved Diagnostics and Empirical Therapy.
Cheng GS; Stednick ZJ; Madtes DK; Boeckh M; McDonald GB; Pergam SA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2243-2249. PubMed ID: 27590103
[TBL] [Abstract][Full Text] [Related]
45. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
46. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant.
Wood W; Deal A; Whitley J; Sharf A; Serody J; Gabriel D; Shea T
Pediatr Blood Cancer; 2011 Sep; 57(3):499-505. PubMed ID: 21384538
[TBL] [Abstract][Full Text] [Related]
47. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.
Wallen H; Gooley TA; Deeg HJ; Pagel JM; Press OW; Appelbaum FR; Storb R; Gopal AK
J Clin Oncol; 2005 May; 23(15):3439-46. PubMed ID: 15824415
[TBL] [Abstract][Full Text] [Related]
48. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
49. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
Feinstein LC; Sandmaier BM; Maloney DG; Maris MB; Gooley TA; Chauncey TR; Hegenbart U; McSweeney PA; Stuart MJ; Forman SJ; Agura EA; Pulsipher MA; Blume KG; Niederwieser DW; Storb RF
Biol Blood Marrow Transplant; 2003 Apr; 9(4):266-72. PubMed ID: 12720219
[TBL] [Abstract][Full Text] [Related]
50. The incidence and prognosis of patients with bacteremia.
Nielsen SL
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183054
[TBL] [Abstract][Full Text] [Related]
51. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.
Fu S; Rybicki L; Abounader D; Andresen S; Bolwell BJ; Dean R; Gerds A; Hamilton BK; Hanna R; Hill BT; Jagadeesh D; Kalaycio ME; Liu HD; Pohlman B; Sobecks RM; Majhail NS
Bone Marrow Transplant; 2015 Oct; 50(10):1326-30. PubMed ID: 26191953
[TBL] [Abstract][Full Text] [Related]
52. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
53. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation.
Shulman DS; London WB; Guo D; Duncan CN; Lehmann LE
Biol Blood Marrow Transplant; 2015 May; 21(5):913-9. PubMed ID: 25667988
[TBL] [Abstract][Full Text] [Related]
54. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation.
Mo XD; Xu LP; Liu DH; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Wang FR; Wang JZ; Liu KY; Huang XJ
Am J Hematol; 2013 Jun; 88(6):497-502. PubMed ID: 23536204
[TBL] [Abstract][Full Text] [Related]
55. Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation.
Mani S; Khera N; Rybicki L; Marneni N; Carraway H; Moore H; Whited H; Majhail NS
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):70-77. PubMed ID: 31810888
[TBL] [Abstract][Full Text] [Related]
56. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors.
Kang JM; Kim YJ; Kim JY; Cho EJ; Lee JH; Lee MH; Lee SH; Sung KW; Koo HH; Yoo KH
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1091-8. PubMed ID: 25708217
[TBL] [Abstract][Full Text] [Related]
57. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
58. Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chang EK; Chanson D; Teh JB; Iukuridze A; Peng K; Forman SJ; Nakamura R; Wong FL; Cai L; Armenian SH
J Clin Oncol; 2021 Mar; 39(8):902-910. PubMed ID: 33417479
[TBL] [Abstract][Full Text] [Related]
59. Improved survival over the last decade in pediatric patients requiring dialysis after hematopoietic cell transplantation.
Rajpal JS; Patel N; Vogel RI; Kashtan CE; Smith AR
Biol Blood Marrow Transplant; 2013 Apr; 19(4):661-5. PubMed ID: 23266833
[TBL] [Abstract][Full Text] [Related]
60. Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients: A Population-Based Cohort Study.
Omland SH; Gniadecki R; Hædersdal M; Helweg-Larsen J; Omland LH
JAMA Dermatol; 2016 Feb; 152(2):177-83. PubMed ID: 26454261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
